Explore high‑quality research‑grade Daraxonrasib (RMC‑6236) from Senova.
As a potent Pan‑RAS(ON) ternary complex inhibitor targeting KRAS G12C‑mutated metastatic solid tumors, Daraxonrasib serves as a critical tool compound for oncology pre‑clinical research.
Senova delivers reliable raw material supply, complete technical documentation and stable batch consistency for your drug‑discovery projects.
Please Note: All products that may involve patent infringement are for R&D only
